Detalhe da pesquisa
1.
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial.
Lancet Oncol
; 19(4): 562-578, 2018 04.
Artigo
Inglês
| MEDLINE | ID: mdl-29611518
2.
Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial.
Lancet Oncol
; 17(11): 1543-1557, 2016 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-27660192
3.
A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS.
Gut
; 64(1): 111-20, 2015 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-24647007
4.
Transdermal Blood Sampling for C-Peptide Is a Minimally Invasive, Reliable Alternative to Venous Sampling in Children and Adults With Type 1 Diabetes.
Diabetes Care
; 47(2): 239-245, 2024 Feb 01.
Artigo
Inglês
| MEDLINE | ID: mdl-38087932
5.
Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD): a phase 2, multicentre, double-blind, randomized, placebo-controlled trial.
Wellcome Open Res
; 5: 49, 2020.
Artigo
Inglês
| MEDLINE | ID: mdl-32399500
6.
Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.
J Clin Oncol
; 32(10): 1031-9, 2014 Apr 01.
Artigo
Inglês
| MEDLINE | ID: mdl-24590654